Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study1.

Author: BühlerSilja, EperonGilles, FurrerHansjakob, FuxChristoph A, HatzChristoph, JaegerVeronika Katharina, JansenStephanie, NeumayrAndreas, NiedrigMatthias, RochatLaurence, SchmidSabine, Schmidt-ChanasitJonas, StaehelinCornelia, VisserLeonardus G, de VisserAdriëtte W

Paper Details 
Original Abstract of the Article :
More people on immunosuppression live in or wish to travel to yellow fever virus (YFV)-endemic areas. Data on the safety and immunogenicity of yellow fever vaccination (YFVV) during immunosuppression are scarce. The aim of this study was to compare the safety and immunogenicity of a primary YFVV bet...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1093/jtm/taaa126

データ提供:米国国立医学図書館(NLM)

Navigating Yellow Fever Vaccination for Immunosuppressed Travelers

This study explores the safety and immunogenicity of a primary yellow fever vaccination (YFVV) in travelers on low-dose methotrexate therapy. It's like charting a course through a desert, seeking to ensure safe passage for those with unique health needs. The study found that primary YFVV was safe and immunogenic in travelers on low-dose methotrexate therapy, providing valuable information for those managing immunosuppressed patients who need to travel to yellow fever-endemic areas.

A Safe and Effective Approach to Yellow Fever Vaccination

This study provides reassuring evidence that primary YFVV is safe and immunogenic in travelers on low-dose methotrexate therapy. It's like finding a safe and reliable path through a treacherous desert, ensuring protection for those with unique health needs. This finding is significant as it offers guidance for managing immunosuppressed patients who need to travel to yellow fever-endemic areas.

Expanding Travel Options for Immunosuppressed Individuals

This research provides a valuable tool for managing immunosuppressed patients who need to travel to yellow fever-endemic areas. It's like discovering a new oasis, opening up possibilities for travel and exploration for individuals with specific health needs. This study helps to address a crucial challenge in managing immunosuppressed patients, ensuring their safety and well-being while allowing them to pursue travel opportunities.

Dr.Camel's Conclusion

This study is a testament to the power of scientific research to improve the lives of those with unique health needs. It's like finding a safe haven in a vast and unforgiving desert, providing reassurance and hope for those facing travel challenges. This research highlights the importance of considering individual patient needs and seeking safe and effective solutions to ensure their well-being.

Date :
  1. Date Completed 2021-07-28
  2. Date Revised 2021-07-28
Further Info :

Pubmed ID

32729905

DOI: Digital Object Identifier

10.1093/jtm/taaa126

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.